Can Treprostinil Change IPF Care?
Inhaled treprostinil resulted in a smaller decline in lung function and fewer clinical‐worsening events than placebo over 52 weeks.
-
By
-
Kathryn Wighton
-
August 12, 2026
-
-
1
The TETON-1 trial evaluated inhaled treprostinil in 598 patients with idiopathic pulmonary fibrosis over 52 weeks.
-
2
Inhaled treprostinil resulted in a smaller decline in forced vital capacity compared to placebo.
-
3
Clinical worsening occurred in 32% of patients receiving treprostinil versus 45% receiving placebo.
-
4
Cough was reported in 55% of patients on treprostinil, compared to 33% on placebo.
-
5
The study noted a high rate of discontinuation of study treatment, with 41% for treprostinil and 33% for placebo.
